5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development Jean L. Grem OriginalPaper Pages: 299 - 313
Conceptual Changes in Cancer Chemotherapy: From an Oral Fluoropyrimidine Prodrug, UFT, to a Novel Oral Fluoropyrimidine Prodrug, S-1, and Low-Dose FP Therapy in Japan Tetsuhiko ShirasakaSusumu YamamitsuTetsuo Taguchi OriginalPaper Pages: 315 - 329
The Tegafur-Based Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidines, UFT/Leucovorin (ORZEL and S-1: a Review of Their Clinical Development and Therapeutic Potential Paulo M. Hoff OriginalPaper Pages: 331 - 342
Preclinical Development of Eniluracil: Enhancing the Therapeutic Index and Dosing Convenience of 5-Fluorouracil Melanie T. PaffDavid P. BaccanariThomas Spector OriginalPaper Pages: 365 - 371
Clinical Development of Eniluracil/Fluorouracil: an Oral Treatment for Patients with Solid Tumors Jeremey LevinJohn Hohneker OriginalPaper Pages: 383 - 390